Schering's Specialty Focus Includes Alzheimer's, Oncology
This article was originally published in Pharmaceutical Approvals Monthly
Schering-Plough's specialty drug pipeline - part of big pharma's overall efforts to hedge against the dwindling primary care market - includes several potential first-in-class or best-in-class compounds addressing oncology, Alzheimer's disease, Parkinson's disease and other specialty areas
You may also be interested in...
Schering-Plough is in a strong financial position for deal-making as it moves into the "build the base" phase of its restructuring initiative, where the firm is actively looking for acquisitions to bolster its R&D portfolio, CEO Fred Hassan said during the company's third quarter earnings call Oct. 20
Antibody-drug conjugates remain a hot area of cancer drug development and Pfizer showed investors some of the novel targets and improved payloads it is advancing.
The company showcased its expanded cancer drug pipeline two months after completing the acquisition of Seagen last year.